Celebrating 25 years Est 1999-2024
*Across 3 years $3395.52 only $1358.21
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health PR Newswire NEW YORK, Sept...
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of...
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection...
PAVmed Provides Business Update and Second Quarter 2024 Financial Results PR Newswire NEW YORK, Aug. 13, 2024...
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results PR Newswire NEW YORK...
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing...
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal...
Lucid Diagnostics to Participate in Upcoming Investor Conferences PR Newswire NEW YORK, Aug. 5, 2024 NEW YORK...
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024 PR Newswire NEW YORK, July 30...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024 PR Newswire NEW...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire NEW YORK, July 23, 2024...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK, July 11, 2024 NEW YORK, July 11, 2024...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.